Akari CEO Corner: 2025 Progress and Path to Clinical Transition In 2026 - January 9, 2026
In this segment, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, provides a corporate update highlighting the Company’s progress in 2025, key scientific and operational milestones achieved, and how these advances position Akari for a potential transition to a clinical-stage oncology company in 2026.
▶︎
Akari CEO Corner Highlighting its Strategic Progress and Path to the Clinical - March 13, 2026
▶︎
Akari on Virtual Investor “What This Means” - December 18, 2025
▶︎
Princess Of Boogie Woogie Delights Everyone
▶︎
Watch Ukrainian Drones OBLITERATE a Russian Jet
▶︎
Tunesien – Japan Highlights | Gruppe F, FIFA WM 2026 | sportstudio
▶︎
The UNTHINKABLE is About to Happen to SpaceX Stock
▶︎
The FULL VIDEO of Trump they didn’t want released
▶︎
Golden Retriever Meets Completely Broken Rescue for the First Time
▶︎
Introducing the American AI Sovereign Wealth Fund Act
▶︎
Akari CEO Corner: ADC Landscape and Akari’s Differentiated PH1 Payload Following ASCO - June 4, 2026
▶︎
Watch Ukrainian Drones OBLITERATE a Russian Plane
▶︎
A Conversation with Nvidia CEO Jensen Huang | Global Conference 2025
▶︎
Akari in Virtual Investor “What This Means” Discussing Partnership with WuXi XDC - April 9, 2026
▶︎
The French Do Not Care About Work
▶︎
Akari Discusses Breakthrough Potential of AKTX-101 and Novel ADC Platform - May 28, 2026
▶︎
Stop Rambling: The 3-2-1 Speaking Trick That Makes You Sound Like A CEO
▶︎
Turn Your TV Into Art | Still Life Vintage Art Slideshow | 1Hr 4k HD Paintings
▶︎
Akari Virtual Investor “What This Means” Discussing its Expanded ADC Pipeline - Feb. 11, 2026
▶︎
The Mag 7 Is Dead. Here's Where Smart Money Is Going Next.
▶︎